Peer-reviewed veterinary case report
LOPP chemotherapy results for dogs with T-cell lymphoma
By Brown, P M et al.·Published in Veterinary and comparative oncology·2018·Department of Oncology, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
- Species:
- dog
Plain-English summary
A group of 31 dogs diagnosed with T-cell lymphoma (a type of cancer affecting the immune system) received a chemotherapy treatment called LOPP, which includes lomustine, vincristine, procarbazine, and prednisolone. The treatment was very effective, with 97% of the dogs responding positively. On average, dogs remained free of symptoms for about 176 days, and the overall survival time was around 323 days. The LOPP protocol was well tolerated, showing minimal side effects compared to other treatments.
People also search for: dog T-cell lymphoma treatment · chemotherapy for dogs with cancer · LOPP protocol for dog lymphoma
Abstract
BACKGROUND: The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy. MATERIALS AND METHODS: Retrospective case study of 31 dogs with naïve T-cell lymphoma treated with a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol. RESULTS: Thirty-one dogs with T cell lymphoma were treated. The overall response rate was 97%. Of the 30 dogs that had a response to LOPP chemotherapy, the median disease free interval was 176 days (range 0-1745 days). The median overall survival time for this study group was 323 days (range 51-1758 days). All deaths in this study were attributable to lymphoma. CONCLUSION: LOPP chemotherapy for T cell lymphoma is well tolerated with a low toxicity profile and an excellent overall response rate. This protocol showed minimal toxicity and comparable disease free interval and survival times for canine high grade T cell lymphoma treated with CHOP.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28508557/